Emmanuel Bachy
Overview
Explore the profile of Emmanuel Bachy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
2849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mozas P, Ould Ammar R, Chartier L, Nastoupil L, Bachy E, Bezsera S, et al.
Br J Haematol
. 2025 Mar;
PMID: 40031898
The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been shown to predict outcomes in follicular lymphoma (FL). Among 1018 patients from the RELEVANCE trial (for previously untreated, high tumour burden FL),...
2.
Galtier J, Mesguich C, Sesques P, Dupont V, Bachy E, Di Blasi R, et al.
Hemasphere
. 2025 Feb;
9(2):e70091.
PMID: 39968186
Primary mediastinal B-cell lymphoma (PMBL) is often cured with dose-dense anthracycline-based regimens but the prognosis at relapse or progression remains poor. While anti-CD19 CAR-T cell therapy has dramatically improved outcomes...
3.
Phina-Ziebin X, Bachy E, Gros F, Di Blasi R, Herbaux C, Bay J, et al.
Blood Adv
. 2025 Jan;
PMID: 39874518
High-grade-B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double hit [HGBL-DH] or triple hit [HGBL-TH]), or not otherwise specified (HGBL-NOS), are considered to be more aggressive diseases among...
4.
Bachy E, Linton K
Blood
. 2025 Jan;
PMID: 39869829
Follicular lymphoma is the most common subtype of indolent lymphoma. Despite multiple trials over the past decade showing improved progression-free survival with new first-line therapeutic strategies -such as anti-CD20 maintenance...
5.
Marouf A, Chaubard S, Lievin R, Michot J, Molinari N, Rossignol J, et al.
Hemasphere
. 2025 Jan;
9(1):e70081.
PMID: 39840381
No abstract available.
6.
Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, et al.
Nat Med
. 2025 Jan;
PMID: 39779930
The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database,...
7.
Falchi L, Hutchings M, Carlo-Stella C, Morschhauser F, Dickinson M, Cartron G, et al.
Haematologica
. 2024 Nov;
PMID: 39605203
Not available.
8.
Sesques P, Karlin L, Massy E, Maarek A, Aussedat G, Lazareth A, et al.
Front Oncol
. 2024 Nov;
14:1436587.
PMID: 39544298
Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus...
9.
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A, et al.
Blood Cancer J
. 2024 Nov;
14(1):197.
PMID: 39511146
No abstract available.
10.
Zinzani P, Izutsu K, Mehta-Shah N, Barta S, Ishitsuka K, Cordoba R, et al.
Lancet Oncol
. 2024 Nov;
25(12):1602-1613.
PMID: 39486433
Background: Peripheral T-cell lymphomas are aggressive non-Hodgkin lymphomas with few treatment options for relapsed or refractory disease. Valemetostat tosylate (valemetostat) is a potent, novel, dual inhibitor of EZH2 and EZH1....